Keywords: fda, clears, xoma/genentech, raptiva, plaque, psoriasis, therapy
FDA clears Xoma/Genentech's Raptiva as plaque psoriasis therapy in adults
Article | 03 November 2003
The US Food and Drug Administration has approved the use ofXoma/Genentech's Raptiva (efalizumab) in the treatment of chronic moderate-to-severe ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
